

Xavier Puñchal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2560082/publications.pdf>

Version: 2024-02-01

219
papers

14,218
citations

18436

62
h-index

22102

113
g-index

239
all docs

239
docs citations

239
times ranked

9029
citing authors

#	ARTICLE	IF	CITATIONS
1	Revisiting characteristics, treatment and outcome of cardiomyopathy in eosinophilic granulomatosis with polyangiitis (formerly Churgâ€“Strauss). <i>Rheumatology</i> , 2022, 61, 1175-1184.	0.9	11
2	Presentation, Diagnosis, and Management of Subglottic and Tracheal Stenosis During Systemic Inflammatory Diseases. <i>Chest</i> , 2022, 161, 257-265.	0.4	10
3	<i>Bartonella and Coxiella</i> infections presenting as systemic vasculitis: case series and review of literature. <i>Rheumatology</i> , 2022, 61, 2609-2618.	0.9	15
4	Efficacy and safety of ustekinumab in Behçet disease: Results from the prospective phase 2 STELABEC trial. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 681-684.	0.6	5
5	French Vasculitis Study Group recommendations for the management of COVID-19 vaccination and prophylaxis in patients with systemic vasculitis. <i>Presse Medicale</i> , 2022, 51, 104107.	0.8	2
6	Biopsy-proven kidney involvement in hypocomplementemic urticarial vasculitis. <i>BMC Nephrology</i> , 2022, 23, 67.	0.8	3
7	Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry. <i>RMD Open</i> , 2022, 8, e002160.	1.8	9
8	FC040: Kidney Transplantation in Childhood-Onset ANCA-Associated Vasculitis: Outcomes in a Multicentre Cohort. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
9	Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. <i>JAMA Network Open</i> , 2022, 5, e2220925.	2.8	18
10	Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Rheumatology</i> , 2021, 60, 4355-4360.	0.9	21
11	Sustained Remission of Granulomatosis With Polyangiitis After Discontinuation of Glucocorticoids and Immunosuppressant Therapy: Data From the French Vasculitis Study Group Registry. <i>Arthritis and Rheumatology</i> , 2021, 73, 641-650.	2.9	8
12	Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. <i>Rheumatology</i> , 2021, 60, 359-365.	0.9	27
13	Characteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 436-441.	1.6	10
14	MO271PROGNOSIS OF NON-PR3 ANCA-ASSOCIATED VASCULITIDES WITH RENAL INVOLVEMENT. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
15	POS011â€“...RENAL AND OVERALL OUTCOMES OF DOUBLE-POSITIVE (ANCA AND ANTI-GBM ANTIBODIES) PATIENTS COMPARED TO ANCA-ASSOCIATED VASCULITIS PATIENTS WITH SEVERE RENAL INVOLVEMENT: A MULTICENTER RETROSPECTIVE STUDY WITH SYSTEMATIC RENAL PATHOLOGY ANALYSIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 269.1-270.	0.5	0
16	Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibodyâ€“Associated Vasculitis: Systematic Review and Metaâ€“Analysis. <i>ACR Open Rheumatology</i> , 2021, 3, 484-494.	0.9	17
17	Significance of eosinophilia in granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. <i>Rheumatology</i> , 2021, , .	0.9	4
18	Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2942-2943.	2.0	3

#	ARTICLE	IF	CITATIONS
19	Off-label use of biologics for the treatment of refractory and/or relapsing granulomatosis with polyangiitis. <i>European Journal of Internal Medicine</i> , 2021, , .	1.0	2
20	Disease Activity and Adverse Events in Patients with ANCA-Associated Vasculitides Undergoing Long-Term Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1665-1675.	2.2	8
21	Patients of 75 years and over with ANCA-associated vasculitis have a lower relapse risk than younger patients: A multicentre cohort study. <i>Journal of Internal Medicine</i> , 2021, , .	2.7	8
22	Reply to the comment on: Microscopic polyangiitis: clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry by Nguyen et al. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 128, 9-10.	0.4	0
23	Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis. <i>Arthritis Care and Research</i> , 2020, 72, 838-849.	1.5	62
24	Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. <i>Journal of Autoimmunity</i> , 2020, 106, 102338.	3.0	43
25	No evident association of nasal carriage of <i>Staphylococcus aureus</i> or its small-colony variants with cotrimoxazole use or ANCA-associated vasculitis relapses. <i>Rheumatology</i> , 2020, 59, 77-83.	0.9	8
26	Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody-associated Vasculitis-related Bronchiectasis: Data from 61 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 1522-1531.	1.0	10
27	Risk of malignancy in patients treated for systemic necrotising vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 431-433.	0.5	7
28	Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Annals of Internal Medicine</i> , 2020, 173, 179-187.	2.0	116
29	Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 879-884.	1.6	21
30	Developments in the Histopathological Classification of ANCA-Associated Glomerulonephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1103-1111.	2.2	47
31	Randomized clinical trials in ANCA-associated vasculitis: a systematic analysis of the WHO - International Clinical Trials Registry Platform. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 130.	1.2	2
32	Granulomatosis with polyangiitis (Wegener's). <i>Joint Bone Spine</i> , 2020, 87, 572-578.	0.8	26
33	Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. <i>Rheumatology</i> , 2020, 59, 2970-2975.	0.9	7
34	Three Patterns of Cutaneous Involvement in Granulomatosis with Polyangiitis. <i>Journal of Advanced Research</i> , 2020, 24, 311-315.	4.4	6
35	ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance. <i>Presse Medicale</i> , 2020, 49, 104031.	0.8	21
36	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2020, 382, 622-631.	13.9	465

#	ARTICLE	IF	CITATIONS
37	Microscopic polyangiitis: Clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry. <i>Journal of Autoimmunity</i> , 2020, 112, 102467.	3.0	25
38	French recommendations for the management of systemic necrotizing vasculitides (polyarteritis) <i>Tj ETQq0 0 0 rgBTj Overlock 10 Tf 50 7</i>	1.2	39
39	OP0030â€¦GRANULOMATOSIS WITH POLYANGIITIS SUSTAINED REMISSION OFF-THERAPY: DATA FROM THE FRENCH VASCULITIS STUDY GROUP REGISTRY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 22.1-22.	0.5	0
40	AB0467â€¦REMISSION AND LOW DISEASE ACTIVITY STATE IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS AND MICROSCOPIC POLYANGIITIS: PREVALENCE AND IMPACT ON DAMAGE ACCRUAL. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1531.1-1532.	0.5	0
41	Reply to the comment of Fayet et al. Obstacles and motivations to influenza and pneumococcal vaccination in patients with rheumatoid arthritis. A qualitative study. <i>Joint Bone Spine</i> , 2019, 86, 119.	0.8	0
42	Tracheobronchial involvement of relapsing polychondritis. <i>Autoimmunity Reviews</i> , 2019, 18, 102353.	2.5	42
43	Inadequate reporting of concomitant medications in rheumatology randomized controlled trials of pharmacologic interventions. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 453-458.	1.6	0
44	118.â€¦VALIDATION OF THE RENAL RISK SCORE FOR ANCA-ASSOCIATED GLOMERULONEPHRITIS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
45	Rheumatoid arthritis-associated bronchiectasis. <i>Lancet, The</i> , 2019, 393, 2035-2036.	6.3	4
46	Ocular involvement in granulomatosis with polyangiitis: A single-center cohort study on 63 patients. <i>Autoimmunity Reviews</i> , 2019, 18, 493-500.	2.5	43
47	Enfermedad de Whipple. <i>EMC - Tratado De Medicina</i> , 2019, 23, 1-6.	0.0	1
48	FRI0278â€¦OFF-LABEL USE OF BIOLOGICAL THERAPIES IN RELAPSING AND/OR REFRACTORY EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS). , 2019, , .		1
49	StratÃ©gies dâ€™immunothÃ©rapie ciblÃ©e au cours des vascularites associÃ©es aux ANCA. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019, 86, 33-38.	0.0	0
50	Targeted immunotherapy strategies in ANCA-associated vasculitis. <i>Joint Bone Spine</i> , 2019, 86, 321-326.	0.8	9
51	Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients. <i>Rheumatology</i> , 2019, 58, 401-409.	0.9	35
52	Atteintes trachÃ©o-bronchiques de la polychondrite atrophiante. <i>Revue Du Rhumatisme Monographies</i> , 2018, 85, 226-232.	0.0	0
53	Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1150-1156.	0.5	139
54	Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1143-1149.	0.5	219

#	ARTICLE	IF	CITATIONS
55	Impaired intracellular pathogen clearance and inflammatory joint disease: Is Whipple's disease a guiding light?. <i>Joint Bone Spine</i> , 2018, 85, 531-536.	0.8	14
56	Reply. <i>Arthritis and Rheumatology</i> , 2018, 70, 151-152.	2.9	1
57	Childhood- versus adult-onset ANCA-associated vasculitides: A nested, matched case-control study from the French Vasculitis Study Group Registry. <i>Autoimmunity Reviews</i> , 2018, 17, 108-114.	2.5	42
58	Mortality in systemic necrotizing vasculitides: A retrospective analysis of the French Vasculitis Study Group registry. <i>Autoimmunity Reviews</i> , 2018, 17, 653-659.	2.5	40
59	Childhood- versus Adult-Onset Polyarteritis Nodosa Results from the French Vasculitis Study Group Registry. <i>Autoimmunity Reviews</i> , 2018, 17, 984-989.	2.5	15
60	Pneumococcal and influenza vaccination rates in patients treated with corticosteroids and/or immunosuppressive therapies for systemic autoimmune diseases: A cross-sectional study. <i>Joint Bone Spine</i> , 2017, 84, 365-366.	0.8	21
61	Very early renal relapse of microscopic polyangiitis after kidney transplantation. <i>Joint Bone Spine</i> , 2017, 84, 107-108.	0.8	1
62	Eosinophilic gastrointestinal disorder preceding Sjögren's syndrome. <i>Joint Bone Spine</i> , 2017, 84, 109-110.	0.8	2
63	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	2.5	32
64	Anti-pentraxin antibodies in autoimmune systemic diseases: Focus on anti-pentraxin-3 autoantibodies. <i>International Reviews of Immunology</i> , 2017, 36, 145-153.	1.5	6
65	Clinical Image: Whipple's Destructive Septic Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 559-559.	2.9	5
66	Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1662-1668.	0.5	159
67	Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey. <i>Arthritis and Rheumatology</i> , 2017, 69, 1862-1870.	2.9	117
68	Perspectives de traitement par biomédicaments dans la granulomatose éosinophilique avec polyangéite (Churg-Strauss). <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 256-261.	0.0	2
69	Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors. <i>Arthritis and Rheumatology</i> , 2017, 69, 2175-2186.	2.9	117
70	Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. <i>Rheumatology</i> , 2017, 56, 1894-1901.	0.9	31
71	Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: A new overlap syndrome. <i>Autoimmunity Reviews</i> , 2017, 16, 1036-1043.	2.5	120
72	Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Report of 26 patients and review of the literature. <i>Autoimmunity Reviews</i> , 2017, 16, 963-969.	2.5	70

#	ARTICLE	IF	CITATIONS
73	Failure of pneumococcal immunization during remission induction treatment of ANCA-associated vasculitis: The Pneumovas Pilot 1 study. <i>Joint Bone Spine</i> , 2017, 84, 643-644.	0.8	10
74	Employment, work disability and quality of life in patients with ANCA-associated vasculitides. The EXPOVAS study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 40-46.	0.4	9
75	Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 176-184.	0.4	7
76	Immunotherapy in Eosinophilic Granulomatosis with Polyangiitis: A New Step Forward?. <i>Journal of Phonetics & Audiology</i> , 2016, 2, .	0.2	1
77	Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. <i>Arthritis and Rheumatology</i> , 2016, 68, 2274-2282.	2.9	84
78	Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?. <i>RMD Open</i> , 2016, 2, e000305.	1.8	9
79	Granulomatosis with polyangiitis according to geographic origin and ethnicity: clinical-biological presentation and outcome in a French population. <i>Rheumatology</i> , 2016, 56, kew423.	0.9	3
80	Manifestations articulaires de la maladie de Whipple. <i>Revue Du Rhumatisme Monographies</i> , 2016, 83, 228-232.	0.0	1
81	Whipple's arthritis. <i>Joint Bone Spine</i> , 2016, 83, 631-635.	0.8	40
82	VAC-04 - Echec de la vaccination antipneumococcique en phase d'attaque du traitement des vascularites A ANCA : l'etude pneumovas pilote 1. <i>Médecine Et Maladies Infectieuses</i> , 2016, 46, 111.	5.1	1
83	Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 141.	1.2	62
84	SAT0351...Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study OF34 Patients. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 794.1-794.	0.5	0
85	Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis. <i>Medicine (United States)</i> , 2016, 95, e3748.	0.4	64
86	Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2016, 68, 690-701.	2.9	101
87	Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients. <i>Journal of Rheumatology</i> , 2016, 43, 1547-1552.	1.0	56
88	Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. <i>Rheumatology</i> , 2016, 55, 291-300.	0.9	170
89	Therapeutic immunomodulation in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Joint Bone Spine</i> , 2016, 83, 7-10.	0.8	4
90	Comment on: First report of FIP1L1-PDGFR β -positive eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2016, 55, 384-385.	0.9	5

#	ARTICLE	IF	CITATIONS
91	Eosinophilic gastrointestinal disorders associated with autoimmune connective tissue disease. <i>Joint Bone Spine</i> , 2016, 83, 479-484.	0.8	27
92	Detection of Anti-Pentraxin-3 Autoantibodies in ANCA-Associated Vasculitis. <i>PLoS ONE</i> , 2016, 11, e0147091.	1.1	30
93	SAT0379â€¦Is Fatigue Immune-Mediated in Primary Sjögren's Syndrome? Data from the Prospective Assess Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 796.2-796.	0.5	0
94	Pituitary Involvement in Granulomatosis With Polyangiitis. <i>Medicine (United States)</i> , 2015, 94, e748.	0.4	61
95	Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?. <i>PLoS ONE</i> , 2015, 10, e0133907.	1.1	19
96	Granulomatosis with polyangiitis: endoscopic management of tracheobronchial stenosis: results from a multicentre experience. <i>Rheumatology</i> , 2015, 54, 1852-1857.	0.9	38
97	Outcomes of patients admitted to intensive care units for acute manifestation of small-vessel vasculitis: a multicenter, retrospective study. <i>Critical Care</i> , 2015, 20, 27.	2.5	28
98	Atypical focal forms of Whipple's disease seen by rheumatologists. <i>Joint Bone Spine</i> , 2015, 82, 56-59.	0.8	14
99	Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty-Five Years or Older: Results of a Multicenter, Open-Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide-Based Induction Therapy. <i>Arthritis and Rheumatology</i> , 2015, 67, 1117-1127.	2.9	150
100	Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. <i>Rheumatology</i> , 2015, 54, 1699-1708.	0.9	49
101	Inflammatory bowel diseases in anti-neutrophil cytoplasmic antibody-associated vasculitides: 11 retrospective cases from the French Vasculitis Study Group. <i>Rheumatology</i> , 2015, 54, 1970-1975.	0.9	37
102	AB0173â€¦Metabolomics in Primary Sjögren's Syndrome: Data from the Assess Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 948.2-948.	0.5	0
103	ANCA-associated vasculitis in patients with primary Sjögren's syndrome: Detailed analysis of 7 new cases and systematic literature review. <i>Autoimmunity Reviews</i> , 2015, 14, 742-750.	2.5	52
104	Sjögren's syndrome complicated by interstitial cystitis: A case series and literature review. <i>Joint Bone Spine</i> , 2015, 82, 245-250.	0.8	20
105	Brief Report: Childhood-Onset Systemic Necrotizing Vasculitides: Long-Term Data From the French Vasculitis Study Group Registry. <i>Arthritis and Rheumatology</i> , 2015, 67, 1959-1965.	2.9	47
106	Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group. <i>Journal of Autoimmunity</i> , 2015, 65, 49-55.	3.0	34
107	Patients with dual MPO- and PR3-ANCA do not present primary systemic necrotizing vasculitis. <i>Joint Bone Spine</i> , 2015, 82, 292-294.	0.8	1
108	Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes. <i>Rheumatology</i> , 2015, 54, 424-432.	0.9	89

#	ARTICLE	IF	CITATIONS
109	Tobacco differentially affects the clinical-biological phenotypes of ANCA-associated vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S-116-21.	0.4	2
110	Poor Survival in Rheumatoid Arthritis Associated with Bronchiectasis: A Family-Based Cohort Study. <i>PLoS ONE</i> , 2014, 9, e110066.	1.1	30
111	Factors Associated with Major Cardiovascular Events in Patients with Systemic Necrotizing Vasculitides: Results of a Longterm Followup Study. <i>Journal of Rheumatology</i> , 2014, 41, 723-729.	1.0	25
112	Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 249.	3.8	241
113	Mucormycosis in systemic autoimmune diseases. <i>Joint Bone Spine</i> , 2014, 81, 303-307.	0.8	12
114	Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients. <i>Journal of Autoimmunity</i> , 2014, 50, 135-141.	3.0	67
115	Relapsing polychondritis. <i>Joint Bone Spine</i> , 2014, 81, 118-124.	0.8	74
116	Ocular inflammatory diseases associated with rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2014, 10, 108-116.	3.5	102
117	Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. <i>Autoimmunity Reviews</i> , 2014, 13, 197-205.	2.5	77
118	Polychondrite chronique atrophiante. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014, 81, 213-219.	0.0	4
119	Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2014, 371, 1771-1780.	13.9	842
120	Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: A french multicenter study. <i>Autoimmunity Reviews</i> , 2014, 13, 1035-1041.	2.5	94
121	Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. <i>Autoimmunity Reviews</i> , 2014, 13, 945-953.	2.5	48
122	Formes atypiques de maladie de Whipple localis�e vues en rhumatologie. <i>Revue Du Rhumatisme (Edition) Tj ETQg</i> , 2014, 80, 100-106.	0.0	0
123	Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2074-2081.	0.5	204
124	A severe Whipple disease with an immune reconstitution inflammatory syndrome: An additional case of thalidomide efficiency. <i>Joint Bone Spine</i> , 2014, 81, 260-262.	0.8	22
125	Treatment of Primary Sjögren Syndrome With Rituximab. <i>Annals of Internal Medicine</i> , 2014, 160, 233-242.	2.0	325
126	OPO218�...Elevated Serum BAFF is Associated with an Increased Risk of Developing A New Systemic Complication: Data from the Prospective ASSESS Cohort. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 145.1-145.	0.5	0

#	ARTICLE	IF	CITATIONS
127	Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. <i>Presse Medicale</i> , 2013, 42, 1317-1330.	0.8	62
128	Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss syndrome) enrolled in two prospective trials. <i>Journal of Autoimmunity</i> , 2013, 43, 60-69.	3.0	168
129	Recommendations for using TNF± antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health. <i>Joint Bone Spine</i> , 2013, 80, 574-581.	0.8	48
130	Whipple's disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 797-803.	0.5	78
131	Therapeutic immunomodulation in systemic vasculitis: Taking stock. <i>Joint Bone Spine</i> , 2013, 80, 374-379.	0.8	15
132	Eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss): Clinical characteristics and longâ€“term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. <i>Arthritis and Rheumatism</i> , 2013, 65, 270-281.	6.7	670
133	Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. A prospective study in 117 patients. <i>Presse Medicale</i> , 2013, 42, 679.	0.8	13
134	Mucormycosis cerebral arteritis mimicking a flare in ANCA-associated vasculitis. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 182.	4.6	11
135	Tracheal and bronchial stenoses in granulomatosis with polyangiitis (Wegener) (GPA). <i>Presse Medicale</i> , 2013, 42, 659-660.	0.8	0
136	L12. Rheumatoid arthritis vasculitis. <i>Presse Medicale</i> , 2013, 42, 527-530.	0.8	6
137	European League Against Rheumatism SjÅ“gren's Syndrome Disease Activity Index and European League Against Rheumatism SjÅ“gren's Syndrome Patientâ€“Reported Index: A Complete Picture of Primary SjÅ“gren's Syndrome Patients. <i>Arthritis Care and Research</i> , 2013, 65, 1358-1364.	1.5	71
138	Central Nervous System Involvement in Whipple Disease. <i>Medicine (United States)</i> , 2013, 92, 324-330.	0.4	83
139	Republished: Whipple's disease. <i>Postgraduate Medical Journal</i> , 2013, 89, 659-665.	0.9	1
140	Rheumatic and Musculoskeletal Features of Whipple Disease: A Report of 29 Cases. <i>Journal of Rheumatology</i> , 2013, 40, 2061-2066.	1.0	40
141	Contribution of antiferritin antibodies to diagnosis of giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1269-1270.	0.5	23
142	Pattern of demyelination occurring during anti-TNF± therapy: a French national survey. <i>Rheumatology</i> , 2013, 52, 868-874.	0.9	120
143	Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary SjÅ“grenâ€“s Syndrome. Data at Enrollment in the Prospective ASSESS Cohort. <i>PLoS ONE</i> , 2013, 8, e59868.	1.1	147
144	Whipple Disease Revealed by Lung Involvement. <i>Chest</i> , 2012, 141, 1595-1598.	0.4	39

#	ARTICLE	IF	CITATIONS
145	Urogenital Manifestations in Wegener Granulomatosis. <i>Medicine (United States)</i> , 2012, 91, 67-74.	0.4	56
146	How to treat refractory arthritis in lupus?. <i>Joint Bone Spine</i> , 2012, 79, 347-350.	0.8	8
147	Abatacept therapy and safety management. <i>Joint Bone Spine</i> , 2012, 79, 3-84.	0.8	49
148	Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the Autoimmunity and Rituximab Registry. <i>Arthritis Care and Research</i> , 2012, 64, 331-339.	1.5	88
149	Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 616-623.	0.5	249
150	Decreased Numbers of Blood Dendritic Cells and Defective Function of Regulatory T Cells in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>PLoS ONE</i> , 2011, 6, e18734.	1.1	62
151	Behçet's disease in East African patients may not be unusual and is an HLA-B51 negative condition: A case series from Mayotte (Comoros). <i>Joint Bone Spine</i> , 2011, 78, 166-170.	0.8	14
152	Tocilizumab in refractory adult Still's disease. <i>Arthritis Care and Research</i> , 2011, 63, 155-159.	1.5	125
153	Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren's syndrome: A national multicentric retrospective study. <i>Arthritis Care and Research</i> , 2011, 63, 1339-1344.	1.5	61
154	Mutations of the cystic fibrosis gene in patients with bronchiectasis associated with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 653-659.	0.5	34
155	Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2010, 77, 558-563.	0.8	26
156	Treatment of polyarteritis nodosa and microscopic polyangiitis without poor prognosis factors: A prospective randomized study of one hundred twenty-four patients. <i>Arthritis and Rheumatism</i> , 2010, 62, 1186-1197.	6.7	179
157	STAT4 is a confirmed genetic risk factor for Sjögren's syndrome and could be involved in type 1 interferon pathway signaling. <i>Genes and Immunity</i> , 2010, 11, 432-438.	2.2	71
158	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1744-1750.	0.5	139
159	Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. <i>Arthritis and Rheumatism</i> , 2009, 61, 108-118.	6.7	98
160	What Should Be Done in Case of Persistent Symptoms after Adequate Antibiotic Treatment for Lyme Disease?. <i>Current Problems in Dermatology</i> , 2009, 37, 191-199.	0.8	5
161	The CGGC insertion/deletion polymorphism of the <i>IRF5</i> promoter is a strong risk factor for primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2009, 60, 1991-1997.	6.7	104
162	Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. <i>Rheumatology</i> , 2009, 48, 1429-1434.	0.9	106

#	ARTICLE	IF	CITATIONS
163	Recurrent and fatal pancytopenia due to repeated colchicine self administration. <i>European Journal of Internal Medicine</i> , 2009, 20, e116-e117.	1.0	1
164	Treatment of Churgâ€Strauss syndrome without poorâ€prognosis factors: A multicenter, prospective, randomized, openâ€label study of seventyâ€two patients. <i>Arthritis and Rheumatism</i> , 2008, 58, 586-594.	6.7	294
165	A paradigm of diagnostic criteria for polyarteritis nodosa: Analysis of a series of 949 patients with vasculitides. <i>Arthritis and Rheumatism</i> , 2008, 58, 1528-1538.	6.7	89
166	What constitutes remission of rheumatoid arthritis?. <i>Joint Bone Spine</i> , 2008, 75, 253-256.	0.8	4
167	Focal Myositis of the Calf following S1 Radiculopathy. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 38, 20-27.	1.6	25
168	Churgâ€Strauss syndrome associated with omalizumab. <i>European Journal of Internal Medicine</i> , 2008, 19, 364-366.	1.0	65
169	Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2008, 359, 2790-2803.	13.9	603
170	Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 278-279.	0.5	68
171	Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 880-884.	0.5	66
172	Tumour necrosis factor receptor 2 (TNFRSF1B) association study in Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1684-1685.	0.5	5
173	Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1610-1615.	0.5	80
174	Whipple's Disease. <i>New England Journal of Medicine</i> , 2007, 356, 55-66.	13.9	574
175	CTLA-4 +49A/G and CT60 gene polymorphisms in primary SjÃ¶gren syndrome. <i>Arthritis Research and Therapy</i> , 2007, 9, R24.	1.6	15
176	Eprodinate for the Treatment of Renal Disease in AA Amyloidosis. <i>New England Journal of Medicine</i> , 2007, 356, 2349-2360.	13.9	240
177	Cultivation of <i>Tropheryma whipplei</i> from the synovial fluid in Whipple's arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 1713-1718.	6.7	41
178	Vasculitides associated with malignancies: Analysis of sixty patients. <i>Arthritis and Rheumatism</i> , 2007, 57, 1473-1480.	6.7	255
179	Association of an <i>IRF5</i> gene functional polymorphism with SjÃ¶gren's syndrome. <i>Arthritis and Rheumatism</i> , 2007, 56, 3989-3994.	6.7	173
180	Association between rheumatoid arthritis and primary biliary cirrhosis. <i>Joint Bone Spine</i> , 2007, 74, 279-281.	0.8	27

#	ARTICLE	IF	CITATIONS
181	Antineutrophil cytoplasmic antibody-associated vasculitides. <i>Joint Bone Spine</i> , 2007, 74, 427-435.	0.8	35
182	Recommendations of the French Society for Rheumatology regarding TNF± antagonist therapy in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2007, 74, 627-637.	0.8	70
183	Isolated vasculitis of the female genital tract: a case series and review of literature. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 451, 1083-1089.	1.4	30
184	Lyme meningoradiculitis: prospective evaluation of biological diagnosis methods. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2007, 26, 685-693.	1.3	24
185	Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. <i>Arthritis Research and Therapy</i> , 2006, 8, R114.	1.6	106
186	Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist. <i>Rheumatology</i> , 2006, 46, 192-199.	0.9	101
187	Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2006, 73, 388-395.	0.8	126
188	Nonpharmacological treatments in early rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2006, 73, 396-402.	0.8	58
189	Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2006, 73, 379-387.	0.8	75
190	Recommendations of the French Society for Rheumatology. TNF± antagonist therapy in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2006, 73, 433-441.	0.8	49
191	Lymphocytic meningitis with infliximab for ulcerative colitis. <i>Gastroenterologie Clinique Et Biologique</i> , 2006, 30, 1420-1422.	0.9	10
192	Panton-Valentine leukocidin-producing <i>Staphylococcus aureus</i> infections: Report of 4 French cases. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 192-195.	1.5	22
193	Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 249-252.	0.5	107
194	No evidence for association between 1858 C/T single-nucleotide polymorphism of PTPN22 gene and primary Sjögren's syndrome. <i>Genes and Immunity</i> , 2005, 6, 457-458.	2.2	39
195	Role and modalities of information and education in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2005, 72, 163-170.	0.8	37
196	Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2005, 72, 222-228.	0.8	43
197	Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2005, 72, 229-234.	0.8	32
198	Incidence of vasculitis in rheumatoid arthritis: Comment on the article by Turesson et al. <i>Arthritis and Rheumatism</i> , 2005, 52, 1620-1620.	6.7	3

#	ARTICLE	IF	CITATIONS
199	Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1379-1380.	0.5	1
200	Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS). <i>Arthritis and Rheumatism</i> , 2004, 50, 1270-1276.	6.7	368
201	Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. <i>Schizophrenia Research</i> , 2004, 66, 21-29.	1.1	63
202	Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. <i>Arthritis and Rheumatism</i> , 2003, 49, 93-100.	6.7	225
203	Whipple's disease. <i>Joint Bone Spine</i> , 2002, 69, 133-140.	0.8	32
204	Polymerase chain reaction testing for <i>Tropheryma whippelii</i> in unexplained isolated cases of arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1130-1132.	6.7	27
205	A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1309-1318.	6.7	480
206	Whipple disease and arthritis. <i>Current Opinion in Rheumatology</i> , 2001, 13, 74-79.	2.0	91
207	Treatment resistant Lyme arthritis caused by <i>Borrelia garinii</i> . <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 284-286.	0.5	28
208	Necrotizing vasculitis of the peripheral nervous system: Nonsystemic or clinically undetectable?. <i>Arthritis and Rheumatism</i> , 1999, 42, 824-825.	6.7	17
209	Increased frequency of cystic fibrosis Δ F508 mutation in bronchiectasis associated with rheumatoid arthritis. <i>European Respiratory Journal</i> , 1999, 13, 1281-1287.	3.1	30
210	Neuralgic amyotrophy and polyarthritis caused by parvovirus B19 infection. <i>Annals of the Rheumatic Diseases</i> , 1998, 57, 262-263.	0.5	20
211	Bronchiectasis in rheumatoid arthritis. <i>Revue Du Rhumatisme: Joint, Bone, Spine Diseases</i> , 1998, 65, 447-50.	0.0	1
212	Prognosis in rheumatoid vasculitis: Comment on the article by Voskuyl et al. <i>Arthritis and Rheumatism</i> , 1996, 39, 1937-1938.	6.7	5
213	<i>Ureaplasma urealyticum</i> destructive septic polyarthritis revealing a common variable immunodeficiency. <i>Arthritis and Rheumatism</i> , 1995, 38, 1524-1526.	6.7	20
214	Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 1618-1629.	6.7	171
215	Temporal doppler-flow studies for suspected giant-cell arteritis. <i>Lancet, The</i> , 1995, 345, 1437-1438.	6.3	23
216	Buerger's disease and antiphospholipid syndrome.. <i>Annals of the Rheumatic Diseases</i> , 1993, 52, 766-766.	0.5	6

#	ARTICLE	IF	CITATIONS
217	10-year assessment of treatment outcome among Cambodian refugees with sputum smear-positive tuberculosis in Khao-I-Dang, Thailand. <i>Tubercle and Lung Disease</i> , 1992, 73, 384-387.	2.1	16
218	Bilateral femoral neuropathy caused by iliacus hematomas during anticoagulation after cardiac catheterization. <i>American Heart Journal</i> , 1992, 123, 262-263.	1.2	10
219	Remission and Lowâ€Disease Activity in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual. <i>Arthritis Care and Research</i> , 0, , .	1.5	2